Advertisement

“Global Multidisciplinary Team Meetings”: Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC)

Published:March 02, 2022DOI:https://doi.org/10.1016/j.clcc.2022.02.006
      Anal cancer is an uncommon malignancy, accounting for < 0.5% of global cancer diagnoses in 2018. However, incidence is increasing, particularly in females.
      • Deshmukh A.A.
      • Suk R.
      • Shiels M.S.
      • et al.
      Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States.
      ,

      Organization, W. H. (2018). Global cancer observatory. Cancer Fact sheets. Ginebra: World Health Organization.

      The mortality rate from anal cancer has increased by 3.1% per year, with higher rates over 50 years of age, highlighting elderly females as a particular risk group.
      • Deshmukh A.A.
      • Suk R.
      • Shiels M.S.
      • et al.
      Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States.
      Histology is predominantly squamous cell carcinomas (SCC; 80%-85%), with both premalignant and malignant lesions almost always consequent to infection with human papillomavirus (HPV) carcinogenic subtypes.
      • Lin C.
      • Franceschi S.
      • Clifford G.M.
      Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.
      Risk factors include coinfection with Human Immunodeficiency Virus (HIV) and chronic immunocompromised state, such as transplant recipients.
      • Colón-López V.
      • Shiels M.S.
      • Machin M.
      • et al.
      Anal cancer risk among people with HIV infection in the United States.

      Abbreviations:

      anal cancer (squamous cell cancer of anus), MDT (multidisciplinary meeting)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Colón-López V.
        • Shiels M.S.
        • Machin M.
        • et al.
        Anal cancer risk among people with HIV infection in the United States.
        J clin oncol. 2018; 36: 68
        • Deshmukh A.A.
        • Suk R.
        • Shiels M.S.
        • et al.
        Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States.
        JNCI: J Nat Cancer Inst. 2020; 112 (2001–2015): 829-838
        • Fossa S.
        • Horwich A.
        • Russell J.
        • et al.
        Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial.
        J clin oncol. 1999; 17 (1146-1146)
        • Glynne-Jones R.
        • Meadows H.
        • Wan S.
        • et al.
        EXTRA–a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
        Int J Radiat Oncol Biol Phys. 2008; 72 (doi:10.1016/j.ijrobp.2007.12.012): 119-126
        • Gouvas N.
        • Gourtsoyianni S.
        • Kalogeridi M.A.
        • Sougklakos J.
        • Vini L.
        • Xynos E.
        Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer.
        Updates Surg. 2021; 73: 7-21
        • Gunderson L.L.
        • Winter K.A.
        • Ajani J.A.
        • et al.
        Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
        J Clin Oncol. 2012; 30 (doi:10.1200/jco.2012.43.8085): 4344-4351
        • Hodges J.C.
        • Das P.
        • Eng C.
        • et al.
        Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement.
        Int J Radiat Oncol* Biol* Physic. 2009; 75: 791-794
        • Holliday E.B.
        • Lester S.C.
        • Harmsen W.S.
        • et al.
        Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes.
        Int J Radiat Oncol* Biol*. 2018; 102: 102-108
        • James R.D.
        • Glynne-Jones R.
        • Meadows H.M.
        • et al.
        Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
        Lancet Oncol. 2013; 14 (doi:10.1016/s1470-2045(13)70086-x): 516-524
        • Jones C.M.
        • Adams R.
        • Downing A.
        • et al.
        Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-c and intensity modulated radiation therapy: evaluation of a national cohort.
        Int J Radiat Oncol Biol Phys. 2018; 101 (doi:10.1016/j.ijrobp.2018.04.033): 1202-1211
        • Kachnic L.A.
        • Winter K.
        • Myerson R.J.
        • et al.
        RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
        Int J Radiat Oncol Biol Phys. 2013; 86 (doi:10.1016/j.ijrobp.2012.09.023): 27-33
        • Lin C.
        • Franceschi S.
        • Clifford G.M.
        Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.
        Lancet Infect Dis. 2018; 18: 198-206
        • Lum C.
        • Prenen H.
        • Body A.
        • Lam M.
        • Segelov E.
        A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape.
        Expert Rev Gastroenterol Hepatol. 2020; 14: 665-680
        • Meulendijks D.
        • Dewit L.
        • Tomasoa N.B.
        • van
        • et al.
        Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
        Br J Cancer. 2014; 111 (doi:10.1038/bjc.2014.467): 1726-1733
      1. Organization, W. H. (2018). Global cancer observatory. Cancer Fact sheets. Ginebra: World Health Organization.

        • Osborne E.M.
        • Eng C.
        • Skibber J.M.
        • et al.
        Hyperfractionated accelerated reirradiation for patients with recurrent anal cancer previously treated with definitive chemoradiation.
        Am J clin oncol. 2018; 41: 632-637
        • Peiffert D.
        • Tournier-Rangeard L.
        • Gérard J.P.
        • et al.
        Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.
        J Clin Oncol. 2012; 30 (doi:10.1200/jco.2011.35.4837): 1941-1948
        • Rao S.
        • Sclafani F.
        • Eng C.
        • et al.
        International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct.
        J clin oncol. 2020; 38: 2510
        • Wang W.
        • Zhou Y.
        • Wang D.
        • Hu K.
        • Zhang F.
        Prophylactic extended-field irradiation in patients with cervical cancer: a literature review.
        Frontiers in Oncology. 2020; : 10